查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087422

呼吸系統疾病檢測市場：按組件、檢測類型、檢體類型、年齡層、疾病類型和最終用戶分類－2026-2032年全球市場預測

Respiratory Disease Testing Market by Component, Test Type, Sample Type, Age Group, Diseases Type, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，呼吸系統疾病檢測市場將成長至 93.2 億美元，複合年成長率為 6.50%。

主要市場統計數據
基準年 2025 59.9億美元
預計年份：2026年 63.4億美元
預測年份 2032 93.2億美元
複合年成長率 (%) 6.50%

介紹

呼吸系統疾病檢測是臨床決策、公共衛生監測、合理使用抗生素、應對感染疾病爆發的核心支柱。流感、呼吸道融合細胞病毒（RSV）、結核病、新冠肺炎（COVID-19）、肺炎、氣喘和慢性阻塞性肺病（COPD）急性加重以及新出現的呼吸道病原體帶來的持續負擔，凸顯了呼吸系統疾病檢測的重要性。世界衛生組織（WHO）指出，結核病仍是世界上最致命的感染疾病之一，預計到2023年將有1,080萬人罹患結核病，凸顯了快速且準確呼吸系統疾病診斷的持續必要性。

呼吸系統偵測領域的變革性變化

新冠疫情後分子診斷技術的建立、多重PCR檢測的廣泛應用以及對分散式檢查需求的日益成長，正在重塑呼吸系統疾病檢測模式。醫療採購負責人優先考慮能夠快速區分病毒和細菌病原體的平台，從而減少不合理使用抗生素，並改善季節性高峰期的分流流程。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過影像解讀、基於症狀的分診、最佳化檢查室工作流程、流行病學預測和改進品管，對呼吸系統疾病檢測整體產生累積影響。 AI 驅動的乳房攝影篩檢影像工具有助於優先處理疑似肺炎、肺結核和 COVID-19 病例，而機器學習模型則可根據檢測量、陽性率、症候群數據和污水監測信息，幫助更早地發現疫情爆發的徵兆。

關鍵區域洞察

亞太地區是呼吸系統疾病檢測領域最具活力的地區之一，這得益於其龐大的患者群體、多個國家沉重的結核病負擔、都市區空氣污染、發達市場人口老齡化以及醫療保健覆蓋範圍的不斷擴大。中國、印度、日本、韓國和澳洲正在加大對分子診斷、公共衛生監測和醫院檢查室現代化改造的投入，而東南亞市場在集中式和社區醫療機構中對流感、新冠病毒、呼吸道合胞病毒和結核病快速篩檢檢測的採用率也在不斷提高。

對關鍵群體的洞察

東協市場的特點是醫療保健體系多元化、都市化加快、跨境移民增多，以及對價格合理、可在醫院和分散式醫療環境中運行的呼吸系統疾病診斷的需求日益成長。在海灣合作理事會（GCC）國家，透過醫療保健轉型計劃、集中採購、對數位醫療的投資以及先進急診醫院的擴建，先進分子診斷平台的應用正在加速推進。

主要國家的概況

美國憑藉其大規模檢測網路、完善的編碼流程和強勁的季節性需求，在多參數呼吸道病原體檢測、即時分子診斷系統和擴大藥房檢測的商業性部署方面處於世界領先地位。加拿大強調公共衛生檢測、公平取得檢測資源和省級採購模式，而墨西哥則在拓展私人診斷和公共監測能力。巴西是拉丁美洲的主要需求中心，其檢測格局受到都市區密度、流感季節性、結核病負擔以及公共和私人檢測機構擴張的影響。

為行業領導者提供的實用建議

產業領導者應優先考慮建立差異化的呼吸系統疾病檢測產品組合，在速度、準確性、成本和臨床效用之間取得平衡。多重檢測方案應根據當地的流行病學情況、臨床指南和保險報銷實際情況進行客製化，而即時檢測（POC​​）平台的設計應旨在簡化工作流程、最大限度地縮短處理時間、廣泛兼容檢體樣本，並在季節性需求高峰期保持可靠的性能。

調查方法

本執行摘要採用結構化的二手調查方法編寫，該方法綜合運用了來自公共衛生機構、監管機構、同行評審文獻、臨床指南和國際疾病監測資訊來源的資訊。主要參考文獻包括世界衛生組織（WHO）、美國疾病管制與預防中心（CDC）、歐洲疾病預防控制中心（ECDC）、各國衛生署、已發表的診斷效能研究。

結論

呼吸系統疾病檢測正在發展成為一個互聯互通、多技術融合的生態系統，旨在支持更快速的診斷、更恰當的治療決策、更有效的抗生素使用以及更具韌性的公共衛生應對措施。下一階段的市場將以多重檢測技術、分散式存取、人工智慧驅動的工作流程以及與監測系統的整合為特徵。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 呼吸系統疾病檢測市場：依組件分類

  • 裝置
  • 試劑和試劑盒
  • 軟體
  • 服務

第8章 呼吸系統疾病檢測市場：依檢測類型分類

  • 分子診斷
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 恒溫環型核酸擴增（LAMP）
  • 影像檢查
    • 胸部X光檢查
    • 電腦斷層掃描（CT）
    • 磁振造影（MRI）
    • 正子斷層掃描（PET）
  • 免疫測量
    • 酵素免疫分析法（ELISA）
    • 化學冷光免疫檢測（CLIA）
    • 螢光免疫分析
    • 免疫測量（RIA）
  • 肺功能測試
    • 肺功能測定
    • 峰值流量計
    • 彌散能力測試（DLCO）
  • 即時檢測（POC​​T）

第9章 呼吸系統疾病檢測市場：依樣本類型分類

  • 呼吸道檢體
    • 痰
    • 支氣管肺泡灌洗（BAL）
    • 氣管抽吸物
    • 鼻咽拭子
  • 血液檢體
    • 全血
    • 血清
    • 電漿
  • 胸腔積水

第10章 呼吸系統疾病檢測市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第11章 呼吸系統疾病檢測市場：依疾病類型分類

  • 病毒性呼吸道疾病
    • COVID-19
    • 流感感染疾病
      • 甲型流感
      • 乙型流感
    • 鼻病毒感染疾病
    • 腺病毒感染疾病
  • 細菌性呼吸道疾病
    • 結核病菌感染感染
    • 肺炎鏈球菌感染
    • 流感病菌感染感染
    • 嗜肺性退伍軍人桿菌感染疾病
  • 黴菌性呼吸道疾病
    • 感染疾病
    • 隱球菌感染疾病
    • 感染疾病

第12章 呼吸系統疾病檢測市場：依最終用戶分類

  • 診斷檢查室
  • 居家醫療
  • 醫院和診所
  • 研究所

第13章 呼吸系統疾病檢測市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 呼吸系統疾病檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 呼吸系統疾病檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • COSMED Srl
  • Danaher Corporation
  • DiaSorin SpA
  • Dragerwerk AG & Co. KGaA
  • F. Hoffmann-La Roche Ltd.
  • Fisher & Paykel Healthcare Corporation Limited
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Masimo Corporation
  • Medtronic plc
  • MGC Diagnostics Corporation
  • NDD Medical Technologies
  • Owlstone Medical Ltd.
  • QIAGEN NV
  • QuidelOrtho Corporation
  • Randox Laboratories Ltd.
  • ResMed Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Verisante Technology, Inc.
  • Visby Medical, Inc.
  • Vyaire Medical Inc.
Product Code: MRR-035AB9C0DAAD

The Respiratory Disease Testing Market is projected to grow by USD 9.32 billion at a CAGR of 6.50% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.99 billion
Estimated Year [2026] USD 6.34 billion
Forecast Year [2032] USD 9.32 billion
CAGR (%) 6.50%

Introduction

Respiratory disease testing has become a core pillar of clinical decision-making, public health surveillance, antimicrobial stewardship, and outbreak preparedness. Demand is supported by the persistent burden of influenza, respiratory syncytial virus (RSV), tuberculosis, COVID-19, pneumonia, asthma and COPD exacerbations, and emerging respiratory pathogens. The World Health Organization reports tuberculosis remains one of the world's leading infectious disease killers, with an estimated 10.8 million people developing TB in 2023, underscoring the ongoing need for rapid, accurate respiratory diagnostics.

The market is shifting from centralized, single-pathogen testing toward integrated molecular panels, point-of-care antigen and molecular platforms, syndromic testing, and digitally connected diagnostics. Hospitals, reference laboratories, urgent care centers, pharmacies, and home-care settings are increasingly evaluating respiratory disease testing solutions based on speed, sensitivity, workflow efficiency, reimbursement fit, specimen type, and the ability to support surveillance reporting.

Transformative Shifts in the Respiratory Testing Landscape

The respiratory disease testing landscape is being reshaped by the normalization of molecular diagnostics after the COVID-19 pandemic, expanded multiplex PCR adoption, and rising demand for decentralized testing. Clinical buyers are prioritizing platforms that can differentiate viral and bacterial etiologies quickly, reducing inappropriate antibiotic use and improving patient triage during seasonal surges.

A second transformative shift is the convergence of diagnostics with digital health infrastructure. Laboratories and providers are integrating respiratory test results with electronic health records, public health reporting systems, and population-level dashboards. This creates competitive advantage for solutions that combine analytical accuracy with connectivity, automation, sample-to-answer workflows, and scalable supply chains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across respiratory disease testing by improving image interpretation, symptom triage, laboratory workflow optimization, epidemiological forecasting, and quality control. AI-enabled chest imaging tools can help prioritize suspected pneumonia, tuberculosis, and COVID-19 cases, while machine learning models support earlier detection of outbreak signals from testing volumes, positivity rates, syndromic data, and wastewater surveillance inputs.

The most commercially relevant AI use cases are those that reduce operational burden without replacing laboratory-grade validation. In practice, AI strengthens demand forecasting, reagent inventory planning, result interpretation support, and clinical decision support when paired with regulated diagnostic platforms. Industry leaders must ensure models are transparent, validated across diverse populations, and aligned with privacy, cybersecurity, and medical device regulations.

Key Regional Insights

Asia-Pacific is one of the most dynamic regions for respiratory disease testing due to large patient populations, high tuberculosis burden in several countries, urban air pollution, aging demographics in developed markets, and expanding healthcare access. China, India, Japan, South Korea, and Australia are investing in molecular diagnostics, public health surveillance, and hospital laboratory modernization, while Southeast Asian markets are increasing adoption of rapid tests for influenza, COVID-19, RSV, and TB screening in both centralized and community settings.

North America remains a high-value region driven by established reimbursement pathways, advanced molecular testing capacity, strong hospital networks, and high awareness of respiratory viruses. Latin America is expanding diagnostic access through public procurement, private laboratory networks, and infectious disease surveillance programs, with Brazil and Mexico serving as major demand centers. Europe benefits from strong regulatory oversight, mature laboratory infrastructure, antimicrobial resistance initiatives, and coordinated surveillance through national agencies and the European Centre for Disease Prevention and Control.

The Middle East is investing in hospital modernization, medical tourism infrastructure, and national preparedness programs, particularly across Gulf markets where advanced laboratory platforms are increasingly embedded in tertiary care systems. Africa presents significant long-term need because of the high burden of TB, pneumonia, HIV-associated respiratory infections, and limited laboratory access in many countries; scalable point-of-care testing, specimen referral networks, mobile diagnostics, and donor-supported programs are central to improving diagnostic coverage.

Key Group Insights

ASEAN markets are characterized by diverse healthcare systems, rising urbanization, cross-border mobility, and growing demand for affordable respiratory diagnostics that can operate in both hospital and decentralized settings. The GCC is accelerating adoption of advanced molecular platforms through healthcare transformation programs, centralized procurement, digital health investment, and expansion of high-acuity hospitals.

The European Union supports respiratory disease testing through harmonized regulatory frameworks, antimicrobial resistance strategies, clinical laboratory quality standards, and cross-border surveillance capacity. BRICS economies collectively represent large-volume opportunities because of population scale, infectious disease burden, expanding domestic manufacturing capabilities, and growing investment in public health laboratories. G7 countries remain innovation hubs for multiplex molecular testing, companion digital tools, regulatory science, and reimbursement-backed clinical adoption, while NATO-aligned health systems increasingly view respiratory pathogen detection as part of health security, military readiness, emergency preparedness, and continuity of essential services.

Key Country Insights

The United States leads in commercial adoption of multiplex respiratory panels, point-of-care molecular systems, and pharmacy-based testing expansion, supported by large laboratory networks, established coding pathways, and strong seasonal demand. Canada emphasizes public health testing, equitable access, and provincial procurement models, while Mexico is expanding private diagnostics and public surveillance capacity. Brazil is a key Latin American demand center, with testing shaped by urban population density, influenza seasonality, TB burden, and public-private laboratory expansion.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong respiratory testing ecosystems through national health systems, reference laboratories, and surveillance networks. Germany and France are particularly important for laboratory automation and molecular diagnostics, while the United Kingdom strengthened genomic and respiratory surveillance infrastructure after COVID-19. Russia remains relevant because of TB burden, respiratory infection surveillance needs, and domestic diagnostic capacity.

China and India are central to global testing volume due to population scale, TB and respiratory infection burden, air pollution-related respiratory illness, and expanding molecular testing infrastructure. Japan prioritizes high-quality diagnostics for aging populations and seasonal respiratory virus management, while South Korea combines strong biotechnology capacity with rapid adoption of advanced testing. Australia benefits from robust public health surveillance, hospital testing capacity, and demand for respiratory diagnostics across both urban centers and remote healthcare settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated respiratory disease testing portfolios that balance speed, accuracy, cost, and clinical utility. Multiplex panels should be aligned with local epidemiology, clinical guidelines, and reimbursement realities, while point-of-care platforms should be designed for simple workflows, minimal hands-on time, broad specimen compatibility, and reliable performance during seasonal demand spikes.

Organizations should strengthen supply chain resilience for swabs, reagents, cartridges, controls, and critical plastics; invest in interoperability with laboratory information systems and electronic health records; and build evidence packages that demonstrate reduced time to diagnosis, improved patient isolation decisions, fewer unnecessary antibiotics, and better antimicrobial stewardship. Partnerships with hospitals, public health agencies, pharmacies, primary care networks, and telehealth providers can accelerate access while improving surveillance value.

Research Methodology

This executive summary is developed using a structured secondary research methodology that triangulates information from public health agencies, regulatory bodies, peer-reviewed literature, clinical guidelines, and international disease surveillance sources. Key reference points include the World Health Organization, U.S. Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, national health ministries, and published diagnostic performance studies.

Market interpretation applies qualitative and quantitative validation across disease burden, testing settings, technology adoption, reimbursement dynamics, procurement behavior, regulatory pathways, and regional healthcare infrastructure. Insights are reviewed for consistency, recency, and relevance to respiratory disease testing, with emphasis on verified trends, epidemiological evidence, and clinically validated diagnostic use cases rather than speculative claims.

Conclusion

Respiratory disease testing is evolving into a connected, multi-technology ecosystem that supports faster diagnosis, better treatment decisions, stronger antimicrobial stewardship, and more resilient public health response. The market's next phase will be defined by multiplex molecular adoption, decentralized access, AI-supported workflows, and integration with surveillance systems.

Organizations that combine clinically validated assays, scalable manufacturing, digital connectivity, regulatory discipline, and region-specific commercialization strategies will be best positioned to capture growth opportunities. As respiratory pathogens continue to create seasonal, endemic, and pandemic risks, accurate and accessible testing will remain essential to healthcare resilience worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Respiratory Disease Testing Market, by Component

  • 7.1. Instruments
  • 7.2. Reagents & Kits
  • 7.3. Software
  • 7.4. Services

8. Respiratory Disease Testing Market, by Test Type

  • 8.1. Molecular Diagnostics
    • 8.1.1. Polymerase Chain Reaction (PCR)
    • 8.1.2. Next Generation Sequencing (NGS)
    • 8.1.3. Loop Mediated Isothermal Amplification (LAMP)
  • 8.2. Imaging Tests
    • 8.2.1. Chest X Ray
    • 8.2.2. Computed Tomography
    • 8.2.3. Magnetic Resonance Imaging (MRI)
    • 8.2.4. Positron Emission Tomography (PET)
  • 8.3. Immunoassays
    • 8.3.1. Enzyme Linked Immunosorbent Assay (ELISA)
    • 8.3.2. Chemiluminescence Immunoassay (CLIA)
    • 8.3.3. Fluorescence Immunoassay
    • 8.3.4. Radioimmunoassay (RIA)
  • 8.4. Pulmonary Function Tests
    • 8.4.1. Spirometry
    • 8.4.2. Peak Flow Meter
    • 8.4.3. Diffusion Capacity Test (DLCO)
  • 8.5. Point of Care Testing (POCT)

9. Respiratory Disease Testing Market, by Sample Type

  • 9.1. Respiratory Specimens
    • 9.1.1. Sputum
    • 9.1.2. Bronchoalveolar Lavage (BAL)
    • 9.1.3. Tracheal Aspirate
    • 9.1.4. Nasopharyngeal Swab
  • 9.2. Blood Based Samples
    • 9.2.1. Whole Blood
    • 9.2.2. Serum
    • 9.2.3. Plasma
  • 9.3. Pleural Fluid

10. Respiratory Disease Testing Market, by Age Group

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Respiratory Disease Testing Market, by Diseases Type

  • 11.1. Viral Respiratory Diseases
    • 11.1.1. COVID 19
    • 11.1.2. Influenza Infections
      • 11.1.2.1. Influenza A
      • 11.1.2.2. Influenza B
    • 11.1.3. Rhinovirus Infection
    • 11.1.4. Adenovirus Infection
  • 11.2. Bacterial Respiratory Diseases
    • 11.2.1. Mycobacterium Tuberculosis Infection
    • 11.2.2. Streptococcus Pneumoniae Infection
    • 11.2.3. Haemophilus Influenzae Infection
    • 11.2.4. Legionella Pneumophila Infection
  • 11.3. Fungal Respiratory Diseases
    • 11.3.1. Aspergillus Infection
    • 11.3.2. Cryptococcus Infection
    • 11.3.3. Histoplasma Infection

12. Respiratory Disease Testing Market, by End Users

  • 12.1. Diagnostic Laboratories
  • 12.2. Home Care Settings
  • 12.3. Hospitals & Clinics
  • 12.4. Research Laboratories

13. Respiratory Disease Testing Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Respiratory Disease Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Respiratory Disease Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Becton, Dickinson and Company
  • 17.3. Bio-Rad Laboratories, Inc.
  • 17.4. bioMerieux SA
  • 17.5. COSMED Srl
  • 17.6. Danaher Corporation
  • 17.7. DiaSorin S.p.A.
  • 17.8. Dragerwerk AG & Co. KGaA
  • 17.9. F. Hoffmann-La Roche Ltd.
  • 17.10. Fisher & Paykel Healthcare Corporation Limited
  • 17.11. GE HealthCare Technologies Inc.
  • 17.12. Hologic, Inc.
  • 17.13. Masimo Corporation
  • 17.14. Medtronic plc
  • 17.15. MGC Diagnostics Corporation
  • 17.16. NDD Medical Technologies
  • 17.17. Owlstone Medical Ltd.
  • 17.18. QIAGEN N.V.
  • 17.19. QuidelOrtho Corporation
  • 17.20. Randox Laboratories Ltd.
  • 17.21. ResMed Inc.
  • 17.22. Seegene Inc.
  • 17.23. Siemens Healthineers AG
  • 17.24. Sysmex Corporation
  • 17.25. Thermo Fisher Scientific Inc.
  • 17.26. Verisante Technology, Inc.
  • 17.27. Visby Medical, Inc.
  • 17.28. Vyaire Medical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESPIRATORY DISEASE TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RESPIRATORY DISEASE TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LOOP MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LOOP MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LOOP MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMAGING TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMAGING TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMAGING TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHEST X RAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHEST X RAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEST X RAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOIMMUNOASSAY (RIA) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RADIOIMMUNOASSAY (RIA) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIOIMMUNOASSAY (RIA) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PULMONARY FUNCTION TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PULMONARY FUNCTION TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PULMONARY FUNCTION TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SPIROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPIROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPIROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEAK FLOW METER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEAK FLOW METER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEAK FLOW METER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIFFUSION CAPACITY TEST (DLCO) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIFFUSION CAPACITY TEST (DLCO) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIFFUSION CAPACITY TEST (DLCO) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE TESTING (POCT) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE TESTING (POCT) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE TESTING (POCT) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RESPIRATORY SPECIMENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESPIRATORY SPECIMENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RESPIRATORY SPECIMENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SPUTUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SPUTUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SPUTUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRACHEAL ASPIRATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TRACHEAL ASPIRATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRACHEAL ASPIRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NASOPHARYNGEAL SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NASOPHARYNGEAL SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NASOPHARYNGEAL SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD BASED SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD BASED SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD BASED SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLEURAL FLUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PLEURAL FLUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PLEURAL FLUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GERIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GERIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GERIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VIRAL RESPIRATORY DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VIRAL RESPIRATORY DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VIRAL RESPIRATORY DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL COVID 19 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL COVID 19 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COVID 19 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFLUENZA INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFLUENZA INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFLUENZA INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFLUENZA A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFLUENZA A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFLUENZA A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFLUENZA B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFLUENZA B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFLUENZA B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL RHINOVIRUS INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL RHINOVIRUS INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RHINOVIRUS INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADENOVIRUS INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ADENOVIRUS INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ADENOVIRUS INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BACTERIAL RESPIRATORY DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BACTERIAL RESPIRATORY DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BACTERIAL RESPIRATORY DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MYCOBACTERIUM TUBERCULOSIS INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MYCOBACTERIUM TUBERCULOSIS INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MYCOBACTERIUM TUBERCULOSIS INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL STREPTOCOCCUS PNEUMONIAE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL STREPTOCOCCUS PNEUMONIAE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL STREPTOCOCCUS PNEUMONIAE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HAEMOPHILUS INFLUENZAE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HAEMOPHILUS INFLUENZAE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HAEMOPHILUS INFLUENZAE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL LEGIONELLA PNEUMOPHILA INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL LEGIONELLA PNEUMOPHILA INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL LEGIONELLA PNEUMOPHILA INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL FUNGAL RESPIRATORY DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL FUNGAL RESPIRATORY DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL FUNGAL RESPIRATORY DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ASPERGILLUS INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ASPERGILLUS INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ASPERGILLUS INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CRYPTOCOCCUS INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CRYPTOCOCCUS INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CRYPTOCOCCUS INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL HISTOPLASMA INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL HISTOPLASMA INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL HISTOPLASMA INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 297. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 299. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 301. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 302. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 303. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2018-2032 (USD MILLION)
  • TABLE 304. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 306. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 307. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 308. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 310. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 311. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 312. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 313. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD BASED SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 324. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY VIRAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 328. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY BACTERIAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY FUNGAL RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
  • TABLE 330. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 335. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 336. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 337. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, 2018-2032 (USD MILLION)
  • TABLE 338. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 340. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE,